Table 3.
Two studies which did not include RT but can be indicative for basal cytokine values.
| Ref | No. of BC Patients and CTR | Treatment (S, RT, CHT, CRT, Combined) | RT TD and d in frs | CHT/HT | Sample Type | Sampling Timepoints | Cytokines | Results |
|---|---|---|---|---|---|---|---|---|
| [42] | 98 | Anti-Her-2 therapy (trastuzumab) | None | No | Biopsy | During resection | FOXP3 | Associated with OS |
| [43] | 96 BC + 30 healthy donors as CTR | Standard treatments after sampling | None | No | Serum | Before any treatment | TGF-β1 | TGF-β1 levels statistically significant and higher in BC patients than in CTR |
Abbreviations for Table 3: breast cancer (BC); healthy control (CTR); forkhead box P3 (FOXP3); human epidermal growth factor receptor-2 (Her-2); overall survival (OS); transforming growth factor beta-1 (TGF-β1).